Innocan Pharma Obtains Indian Patent for Liposome-Based CBD Drug

Innocan Pharma Corporation, a leader in the pharmaceutical and biotechnology sectors, is pleased to declare that it has received a patent in India for a prolonged-release pharmaceutical formulation that uses liposomes to encapsulate cannabinoids.

This granted patent secures Innocan's synthetic Cannabidiol-loaded Liposome Injection Platform (LPT-CBD), which is intended for accurate dosing and prolonged release of Synthetic CBD into the bloodstream. LPT-CBD obtained favorable responses from the U.S. Food and Drug Administration (FDA) after a productive pre-IND meeting aimed at progressing its development as a non-opioid option for chronic pain management. The Indian patent, awarded in a pharmaceutical sector valued at US $55 billion (Bain & Company), enhances Innocan's international patent filings, bolstering the proprietary worth of its innovative liposome-driven cannabinoid technology.

Developed in partnership with Professor Chezy Barenholz and Dr. Ahuva Cern from the Hebrew University in Jerusalem, the liposomal drug delivery system enables extended exposure and enhances the bioavailability and therapeutic impacts of cannabinoids.

Professor Chezy Barenholz the Head of Innocan's Advisory Board stated, "The approval of this patent is a testament to the dedication and expertise of our development teams in driving innovation. Liposomal synthetic cannabidiol (LPT-CBD) is the first drug product in our pipeline that we are currently advancing under this intellectual property portfolio."